Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04506073 · ClinicalTrials.gov registry record · Phase 2
Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT04506073 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 45 participants.
The verdict
NCT04506073, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
Interventions
- DRUG Placebo
- DRUG Mesenchymal Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2023-07-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04506073
The ClinicalTrials.gov registry entry for NCT04506073 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04506073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04506073 about?
NCT04506073 is a clinical study titled "Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease". The purpose of this study is to select the safest and most effective number of repeat doses of allogeneic bone marrow-derived mesenchymal stem cell (MSC) infusions to slow the progression of Parkinson's disease (PD).
What is the current status of trial NCT04506073?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2020-11-09. Estimated completion is 2023-07-30.
What interventions are being tested in trial NCT04506073?
The interventions under investigation include: Placebo (DRUG), Mesenchymal Stem Cells (DRUG).
Who is sponsoring clinical trial NCT04506073?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.